MX2016010365A - Derivados de azucares que comprenden restos que contienen azufre, metodos para prepararlos y metodos para emplearlos en el tratamiento de mps iiic. - Google Patents

Derivados de azucares que comprenden restos que contienen azufre, metodos para prepararlos y metodos para emplearlos en el tratamiento de mps iiic.

Info

Publication number
MX2016010365A
MX2016010365A MX2016010365A MX2016010365A MX2016010365A MX 2016010365 A MX2016010365 A MX 2016010365A MX 2016010365 A MX2016010365 A MX 2016010365A MX 2016010365 A MX2016010365 A MX 2016010365A MX 2016010365 A MX2016010365 A MX 2016010365A
Authority
MX
Mexico
Prior art keywords
methods
same
treatment
sulfur
sugar derivatives
Prior art date
Application number
MX2016010365A
Other languages
English (en)
Inventor
Boyd Robert
Lee Gary
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2016010365A publication Critical patent/MX2016010365A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

En la presente se describen compuestos que son azúcares, iminoazúcares y azaazúcares modificados, y métodos para prepararlos. Uno o más de estos compuestos modificados contienen sulfatos, sulfitos, sulfamatos y/o sulfonamidas. También se describen composiciones/formulaciones farmacéuticas que comprenden estos compuestos, así como también métodos que emplean estos compuestos que son azúcares modificados para el tratamiento de MPS IIIC (que también se denomina Sanfilippo de tipo C).
MX2016010365A 2014-02-12 2015-02-12 Derivados de azucares que comprenden restos que contienen azufre, metodos para prepararlos y metodos para emplearlos en el tratamiento de mps iiic. MX2016010365A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461938924P 2014-02-12 2014-02-12
PCT/US2015/015557 WO2015123385A1 (en) 2014-02-12 2015-02-12 Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of mps iiic
US14/620,283 US9598438B2 (en) 2014-02-12 2015-02-12 Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC

Publications (1)

Publication Number Publication Date
MX2016010365A true MX2016010365A (es) 2016-11-30

Family

ID=53774364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010365A MX2016010365A (es) 2014-02-12 2015-02-12 Derivados de azucares que comprenden restos que contienen azufre, metodos para prepararlos y metodos para emplearlos en el tratamiento de mps iiic.

Country Status (13)

Country Link
US (2) US9598438B2 (es)
EP (1) EP3105235B1 (es)
JP (1) JP2017505350A (es)
KR (1) KR20160113720A (es)
CN (1) CN105992758B (es)
AU (2) AU2015217172B2 (es)
CA (1) CA2939380A1 (es)
EA (1) EA201691603A1 (es)
ES (1) ES2771849T3 (es)
IL (1) IL247141A0 (es)
MX (1) MX2016010365A (es)
TW (1) TW201613861A (es)
WO (1) WO2015123385A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
NL2021840B1 (en) * 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DE3722788A1 (de) * 1987-07-10 1989-01-19 Bayer Ag Chirale 6-hydroxymethylenverzweigte 3-amino-4,5-dihydroxypiperidine, zwischenprodukte zu ihrer herstellung, verfahren zu ihrer herstellung und ihre verwendung
CA2109085C (en) 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
AU3595500A (en) * 1999-02-12 2000-08-29 G.D. Searle & Co. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
US6774140B1 (en) * 1999-05-11 2004-08-10 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
CA2373183C (en) * 1999-05-11 2009-12-08 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
WO2008025170A1 (en) * 2006-08-31 2008-03-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US20110237538A1 (en) * 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010118283A1 (en) * 2009-04-09 2010-10-14 Amicus Therapeutics, Inc. Methods for preventing and/or treating lysosomal storage disorders
CA2778349C (en) * 2009-10-19 2018-12-04 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating lysosomal storage disorders
CA2842015A1 (en) * 2011-07-20 2013-01-24 Universite Pierre Et Marie Curie (Paris 6) Imino-sugar c-glycosides, preparation and use thereof
EP2831043B1 (en) * 2012-03-27 2022-07-27 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system

Also Published As

Publication number Publication date
EP3105235B1 (en) 2019-11-06
EA201691603A1 (ru) 2016-11-30
IL247141A0 (en) 2016-09-29
TW201613861A (en) 2016-04-16
CN105992758A (zh) 2016-10-05
WO2015123385A1 (en) 2015-08-20
CA2939380A1 (en) 2015-08-20
KR20160113720A (ko) 2016-09-30
AU2015217172B2 (en) 2019-09-19
AU2019222876A1 (en) 2019-09-26
EP3105235A1 (en) 2016-12-21
AU2015217172A1 (en) 2016-08-25
JP2017505350A (ja) 2017-02-16
ES2771849T3 (es) 2020-07-07
US9598438B2 (en) 2017-03-21
CN105992758B (zh) 2021-08-31
US20170190665A1 (en) 2017-07-06
US20150225420A1 (en) 2015-08-13

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
MX2019001125A (es) Inhibidores de cinasa macrociclica.
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
MX2017008520A (es) Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
JOP20200152A1 (ar) مركبات حلقية كبرى لعلاج مرض
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
GB2541571A (en) Pharmaceutical compositions
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX2017006694A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2022006817A (es) Formulaciones/composiciones que comprenden un inhibidor de btk.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2017012342A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades,.
TW201613861A (en) Sugar derivatives comprising sulfur-containing moieties and methods of making same and methods of using the same for the treatment of MPS IIIC
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
WO2018211324A8 (en) Prodrugs for the treatment of disease
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.